Bisphosphonates and Thigh Bone Fractures

Long Term Bisphosphonates Possibly Increase Thigh Bone Fractures

The American Society of Bone and Mineral Research (ASBMR's) Task Force released important information to the FDA on the potential association between long term treatment with the class of osteoporosis drugs known as bisphosphonates and a rare but serious type of fracture of the femur thigh bone.

Bisphosphonates (i.e. Fosamax is a bisphosphonate) have long been effective in reducing common bone fractures for people with osteoporosis. Although it is unclear if bisphosphonates are the cause, these unusual femur fractures have been identified in patients taking these drugs.

The FDA recommends that healthcare professionals be aware of the possible risk of atypical femur fractures in patients taking bisphosphonates.